CD19 and neoplasm: In prostate or breast cancer, IL-10+CD19+ cells suppress effector immune cells in the tumor microenvironment by producing IL-10, and promote cancer metastasis by inducing regulatory T cells (Tregs) and releasing anti-inflammatory mediators [21].